Document is current
Any future updates will be listed below
-
Authors
Chen, Xiaoxin
Huang, Xiaodong https://orcid.org/0000-0003-0898-1352
Ma, Qinhai
Kuzmič, Petr https://orcid.org/0000-0001-5250-8381
Zhou, Biao
Zhang, Sai
Chen, Jizheng
Xu, Jinxin https://orcid.org/0000-0002-1680-7533
Liu, Bin
Jiang, Haiming
Zhang, Wenjie
Yang, Chunguang
Wu, Shiguan
Huang, Jianzhou
Li, Haijun
Long, Chaofeng
Zhao, Xin
Xu, Hongrui
Sheng, Yanan
Guo, Yaoting
Niu, Chuanying
Xue, Lu
Xu, Yong
Liu, Jinsong https://orcid.org/0000-0003-2317-0558
Zhang, Tianyu https://orcid.org/0000-0001-5647-6014
Spencer, James https://orcid.org/0000-0002-4602-0571
Zhu, Zhenzhen
Deng, Wenbin https://orcid.org/0000-0002-8897-4891
Chen, Xinwen
Chen, Shu-Hui https://orcid.org/0009-0002-8375-7975
Zhong, Nanshan https://orcid.org/0000-0003-2274-1427
Xiong, Xiaoli https://orcid.org/0000-0002-4632-9122
Yang, Zifeng https://orcid.org/0000-0002-2681-4171
- License Information
-
More Information
Article History
Received: 27 February 2023
Accepted: 22 January 2024
First Online: 29 March 2024
Competing interests
: Xiaoxin Chen, J.H., H.L. and C.L. are employees of Guangdong Raynovent Biotech, which holds the patent of RAY1216. Guangdong Raynovent Biotech provided the RAY1216 molecule used in this study and was responsible for the chemical characterization of RAY1216 and the in vivo and in vitro pharmacokinetic studies. The Raynovent company is not involved in the interpretation of the other results reported in this study and provides no funding to the other parties. P.K. is the author and distributor of the software package DynaFit. DynaFit licenses are available free of charge to all academic, educational and non-profit research institutions. The other authors declare no competing interests.
